Insider Selling: Liquidia (NASDAQ:LQDA) CEO Sells 25,000 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 25,000 shares of the stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $42.09, for a total value of $1,052,250.00. Following the completion of the sale, the chief executive officer owned 1,348,095 shares in the company, valued at approximately $56,741,318.55. The trade was a 1.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

• On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.10, for a total value of $1,002,500.00.
• On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The shares were sold at an average price of $40.60, for a total value of $764,863.40.
• On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.14, for a total value of $1,003,500.00.
• On Tuesday, April 14th, Roger Jeffs sold 3,300 shares of Liquidia stock. The shares were sold at an average price of $40.00, for a total value of $132,000.00.
• On Monday, April 13th, Roger Jeffs sold 32,744 shares of Liquidia stock. The shares were sold at an average price of $38.37, for a total value of $1,256,387.28.
• On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total value of $859,891.96.
• On Thursday, April 9th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total value of $1,003,000.00.

Liquidia Stock Up 0.3%

Shares of NASDAQ LQDA traded up $0.14 during mid-day trading on Thursday, hitting $42.28. The company had a trading volume of 1,196,501 shares, compared to its average volume of 1,625,170. The company has a market capitalization of $3.76 billion, a PE ratio of -50.94 and a beta of 0.41. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.01 and a quick ratio of 1.84. Liquidia Corporation has a 1-year low of $11.85 and a 1-year high of $46.67. The business’s 50-day simple moving average is $36.79 and its 200 day simple moving average is $34.57.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The business had revenue of $92.02 million for the quarter, compared to analysts’ expectations of $87.49 million. Liquidia’s revenue was up 3072.4% on a year-over-year basis. On average, analysts predict that Liquidia Corporation will post 1.75 earnings per share for the current year.

Institutional Investors Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently modified their holdings of LQDA. Farallon Capital Management LLC lifted its position in shares of Liquidia by 102.1% during the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after acquiring an additional 4,326,876 shares during the period. TCG Crossover Management LLC acquired a new stake in shares of Liquidia during the 3rd quarter valued at approximately $38,887,000. Caprock Group LLC acquired a new stake in shares of Liquidia during the 3rd quarter valued at approximately $37,114,000. MPM Bioimpact LLC lifted its position in shares of Liquidia by 600.4% during the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after acquiring an additional 1,200,869 shares during the period. Finally, Voloridge Investment Management LLC acquired a new stake in shares of Liquidia during the 3rd quarter valued at approximately $12,571,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on LQDA shares. Needham & Company LLC raised their price target on Liquidia from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Liquidia in a report on Thursday, March 5th. Oppenheimer lifted their price objective on Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a report on Thursday, March 12th. BTIG Research lifted their price objective on Liquidia from $49.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Finally, Jefferies Financial Group lifted their price objective on Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, January 13th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.44.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).